Physician profile
Linda Huffer
NPI 1346310885
$4,938.02
in general payments reported to CMS, 2019-2025
14 companies · $1,873 in 2025
The $1,873 reported for 2025 was more than what 82% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $112 · 2021: $274 · 2022: $181 · 2023: $2,090 · 2024: $408 · 2025: $1,873.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,571 · Food and Beverage: $1,799.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,571.29 |
| Food and Beverage | $1,799.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,892.52 | 2020-2025 | Watchman Access System, Emblem Mri S-Icd, General - Therapies |
| Abbott Laboratories | $1,732.85 | 2024-2025 | Aveir, Mitraclip |
| Medtronic, INC. | $319.77 | 2023-2024 | Micra, Cobalt Dr Mri Surescan, Selectsecure |
| Biosense Webster, INC. | $273.38 | 2021-2024 | Carto 3 |
| Biotronik INC. | $151.86 | 2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $140.49 | 2021-2024 | Lifevest |
| Atricure, INC. | $139.64 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $88.54 | 2021-2024 | Farxiga, Wainua |
| Novartis Pharmaceuticals Corporation | $52.82 | 2023-2024 | |
| Amgen INC. | $43.40 | 2023-2024 | Repatha |
| Alnylam Pharmaceuticals INC. | $29.54 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $29.39 | 2021-2023 | Eliquis |
| Janssen Pharmaceuticals, INC | $28.19 | 2024 | Xarelto |
| Axonics, INC. | $15.63 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Linda Huffer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.